Catalyst Brief

← Calendar

Readoutin 14d

BeOne Medicines — Zanubrutinib

Phase 3 primary completion: A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib.

Date
Dec 2026
Type
Readout
Indication
B-cell Malignancies

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.